Digest Network Come funziona
Network
/
Società
Pa
Non verificato

Parabilis Medicines

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOncologiaSalute

12 comunicati stampa

Guarda tutti i comunicati
21/11/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Fiere
Industria
Parabilis Medicines Highlights Promising Preliminary Clinical Results in Patients with Adamantinomatous Craniopharyngioma from Ongoing FOG-001 Clinical Trial at SNO 2025
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
12/11/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Parabilis Medicines Receives FDA Fast Track Designation for FOG-001, the First and Only Direct Inhibitor of the β-catenin:TCF Interaction, for the Treatment of Desmoid Tumors
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
30/10/2025
Eventi
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
CORRECTING and REPLACING Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NCI-EORTC 2025
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
24/10/2025
Eventi
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Parabilis Medicines Presents Clinical and Preclinical Data Demonstrating Broad Potential of Helicon™ Peptides at AACR-NCI-EORTC 2025
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
17/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Analisi di mercato
Parabilis Medicines Presents Clinical Data Demonstrating First-Ever Drugging of Key Cancer Driver with FOG-001
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
03/09/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato del lavoro
Parabilis Medicines Appoints Fawzi Benzaghou, M.D., as Chief Medical Officer
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
30/05/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Medical Meetings
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
25/04/2025
Industria
Eventi
Oncologia
Salute
Sanità
Medicina nucleare
Medicina - Varie
Farmaceutica
Biotecnologia
Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
23/04/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Parabilis Medicines to Present First Preclinical Data on ERG Degrader Program at AACR Annual Meeting
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0
23/01/2025
Eventi
Industria
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Parabilis Medicines to Present Trial-in-Progress Poster on Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at ASCO Gastrointestinal Cancers Symposium
Fonte
Parabilis Medicines
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0